Tag - Corbus Pharmaceuticals

Inside the small Norwood biotech that’s making investors swoon

Ziad2022-11-25T14:05:53-05:00The top-performing public biotech in Massachusetts over the past year is located in a nondescript brick building with no signage, located along a stretch of highway in Norwood that is better known for its car dealerships than drug developers. Investors in Corbus Pharmaceuticals don’t much seem to mind. The 3-year-old company, situated some 25 miles south of Cambridge and the bustling biotech hub of Kendall Square, has seen its stock price increase more than 400 percent since March 2016, putting it...

Corbus Pharmaceuticals Reports 2016 Financial Results and Provides 2017 Business Update

Ziad2022-11-25T14:05:54-05:00Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) („Corbus” or the „Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today its financial results for the year ended December 31, 2016. Read more >>

Corbus Pharmaceuticals to Present Gene Expression Data from Recent Phase 2 Systemic Sclerosis Study Demonstrating JBT-101 Inhibits Inflammation and Fibrosis Pathways

Ziad2022-11-25T14:05:54-05:00Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Michael L. Whitfield, Ph.D., Professor of Molecular and Systems Biology, Dartmouth Geisel School of Medicine and Scientific Founder of Celdara Medical, LLC, will present data demonstrating JBT-101 treatment of systemic sclerosis patients inhibits gene expression of key regulatory proteins in molecular pathways associated with activating inflammation and fibrosis, while increasing gene expression in...

Corbus Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference

Ziad2022-11-25T14:05:54-05:00Corbus Pharmaceuticals Holdings, Inc., a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer, will present at the Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8 at 10:40 a.m. ET in Boston, MA. Read more >>

Corbus Pharmaceuticals Receives Orphan Designation for JBT-101 for the Treatment of Systemic Sclerosis in the European Union

Ziad2022-11-25T14:05:55-05:00Corbus Pharmaceuticals Holdings, Inc. (CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that the European Commission has granted Orphan Designation in the European Union ("EU") for the Company's novel synthetic oral endocannabinoid-mimetic drug, JBT-101 ("Resunab") for the treatment of systemic sclerosis. Read more >>

Why Corbus Pharmaceuticals Holdings, Inc. Stock Rocketed 412% Upwards in 2016

Ziad2022-11-25T14:05:55-05:00Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) thrilled investors with a 412.1% gain last year, according todata from S&P Global Market Intelligence Opens a New Window. . Positive mid-stage clinical trial results for its lead drug, Resunab, lifted the stock and ignited hope for further expansion in the future. Read more >>

Corbus Concludes Phase II study of Cystic Fibrosis Candidate

Ziad2022-11-25T14:06:05-05:00Corbus Pharmaceuticals Holdings, Inc. CRBP , recently announced that it has concluded Phase II trial evaluating pipeline candidate, JBT-101 (resunab), for the treatment of cystic fibrosis (CF). Read more >>

Shares Bringing Holiday Cheer For Investors: Corbus Pharmaceuticals Holdings, Inc.

Ziad2022-11-25T14:06:05-05:00Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) have climbed in the previous month. During that time period, shares are up 6.88% which has provided some nice profits for investors who may be looking to take advantage of the recent gains. Focusing in on the past five trading days, shares have changed 4.27%. Year-to-date, the stock has performed 418.18%. Read more >>

Two Biotech Stocks Are Just So Hot Right Now (Corbus Pharmaceuticals Holdings, Inc.)

Ziad2022-11-25T14:06:06-05:00On November 14, 2016 Corbus Pharmaceuticals Holdings, Inc. (CRBP) announced positive topline results from its Phase 2 study evaluating Resunab (“JBT-101”) for the treatment of diffuse cutaneous systemic sclerosis (“systemic sclerosis”). JBT-101 out-performed placebo in the American College of Rheumatology (ACR) Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) score, reaching 33% at week 16, versus 0% for placebo. Read more >>

Tiny Corbus posts midstage win–just–with resunab in systemic sclerosis

Ziad2022-11-25T14:06:06-05:00The little-known small cap Corbus Pharmaceuticals ($CRBP), last year touted as a rival to Vertex ($VRTX), has published positive top-line results from its experimental med resunab in patients with a disease that can cause major fibrosis throughout the body. Read more >>